Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Q32 Bio Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001661998.
Disclosed value leader
Boxer Capital Management, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- QTTB on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001661998
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Q32 Bio Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
Boxer Capital Management,...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 17%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 17%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
17%
Boxer Capital Management, LLC
13%
BIOTECHNOLOGY VALUE FUND L P
10%
Sirenia Capital Management LP
9.9%
RA CAPITAL MANAGEMENT, L.P.
9.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
17%
|
$22,703,928
4,127,987 shares
|
+$10,312,500 | 28 May 2026 |
| Boxer Capital Management, LLC |
13D/G
|
13%
|
$37,886,199
3,149,310 shares
|
$0 | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$13,021,382
2,367,524 shares
|
$0 | 28 May 2026 |
| Sirenia Capital Management LP |
13D/G
|
9.9%
|
$12,138,117
2,057,308 shares
|
$0 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
9.8%
|
$12,828,514
2,332,457 shares
|
$0 | 28 May 2026 |
| Opaleye Management Inc. |
13F
13D/G
Company
|
8.6%
from 13D/G
|
$8,064,984
1,256,228 shares
|
— | 31 Mar 2026 |
| Point72 Asset Management, L.P. |
13D/G
|
5.7%
|
$5,656,731
958,768 shares
|
-$6,481,386 | 31 Mar 2026 |
| Carlyle Group Inc. |
13D/G
13F
The Carlyle Group Inc. · Company
|
4.1%
|
$8,321,572
691,735 shares
|
$0 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$59,783,395.
Buys
$60,000,000
Insiders: 4
Sells
$216,605
Insiders: 3
Net
+$59,783,395
Shares: +7,433,992
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,500,000
Shares: 66,008
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 7,500,000 | 0 | $60,000,000 | $0 | +$60,000,000 |
| 3-6 | 0 | 16,706 | $0 | $75,418 | -$75,418 |
| 6-9 | 0 | 31,578 | $0 | $109,266 | -$109,266 |
| 9-12 | 0 | 17,724 | $0 | $31,921 | -$31,921 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 33 reporting-owner rows connected to Q32 Bio Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
33
Largest Forms 3/4/5 holder
ORBIMED ADVISORS LLC
Net 12M change
+$59,783,395
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $6,286,681 | +$15,000,000 | +239% | Mixed | 28 May 2026 |
| Diyong Xu | Director, 10%+ Owner | $5,171,333 | +$15,000,000 | +290% | Mixed | 12 Jun 2026 |
| OrbiMed Genesis GP LLC | Director, 10%+ Owner | $5,000,000 | +$15,000,000 | +300% | Filing P/S | 28 May 2026 |
| OrbiMed Capital GP VII LLC | Director, 10%+ Owner | $5,000,000 | +$15,000,000 | +300% | Filing P/S | 28 May 2026 |
| Atlas Venture Opportunity Fund Ill, L.P. | Other* | $4,012,500 | Median | 26 May 2026 | ||
| Atlas Venture Associates Opportunity III, LLC | Other* | $4,012,500 | Median | 26 May 2026 | ||
| Atlas Venture Associates Opportunity III, L.P. | Other* | $4,012,500 | Median | 26 May 2026 | ||
| W. Bradford Smith | Chief Financial and Business Officer and Treasurer | $2,899,867 | Mixed | 23 Feb 2023 | ||
| Michael L. Blum | Chief Commercial Officer | $1,415,233 | Mixed | 23 Feb 2023 | ||
| Jason Campagna | Chief Medical Officer | $1,221,995 | Mixed | 24 Feb 2025 | ||
| Atlas Venture Fund X, L.P. | 10%+ Owner | $1,194,801 | Mixed | 25 Mar 2024 | ||
| Jodie Pope Morrison | CEO, Director | $1,052,455 | -$141,445 | -12% | Mixed | 25 Feb 2026 |
| Shelia M. Violette | Chief Scientific Officer | $615,686 | -$18,093 | -2.9% | Mixed | 25 Feb 2026 |
| Lee Kalowski | CFO and President | $424,558 | -$57,067 | -12% | Mixed | 25 Feb 2026 |
| Timothy P. Kelly | Chief Operating Officer | $383,965 | Mixed | 24 Feb 2022 | ||
| Isaac Manke | Director | $378,858 | Mixed | 30 Jun 2026 | ||
| Iwicki Mark T. | Director | $342,666 | Mixed | 12 Jun 2026 | ||
| Steven Gillis | Director | $308,660 | Mixed | 14 Jun 2023 | ||
| Jeffrey Poulton V | Director | $308,660 | Mixed | 14 Jun 2023 | ||
| Matthew R. Patterson | Director | $308,660 | Mixed | 14 Jun 2023 |
Recent insider transactions for Q32 Bio Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Isaac Manke | QTTB | Common Stock | Options Exercise | 53,521 | 53,521 | 30 Jun 2026 | Direct | |||
| Isaac Manke | QTTB | Stock Option (Right to Buy) | Options Exercise | -100% | -53,521 | 0 | 30 Jun 2026 | Direct | ||
| Kathleen Laporte | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Iwicki Mark T. | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Isaac Manke | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Arthur Tzianabos | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| David S. Grayzel | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Mary Thistle | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Diyong Xu | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Sven Ante Lundberg | QTTB | Stock Option (Right to Buy) | Award | 9,810 | 9,810 | 12 Jun 2026 | Direct | |||
| Diyong Xu | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Lee Kalowski | QTTB | Common Stock | Sale | -10% | $18,035 | $4.51 | -3,995 | 35,943 | 25 Feb 2026 | Direct |
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -10% | $44,674 | $4.51 | -9,896 | 89,104 | 25 Feb 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Sale | -4.82% | $12,708 | $4.51 | -2,815 | 55,569 | 25 Feb 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Award | 67.5% | 37,500 | 93,069 | 24 Feb 2026 | Direct | ||
| Jodie Pope Morrison | QTTB | Common Stock | Award | 148.1% | 132,000 | 221,104 | 24 Feb 2026 | Direct | ||
| Lee Kalowski | QTTB | Common Stock | Award | 148.2% | 53,250 | 89,193 | 24 Feb 2026 | Direct | ||
| David S. Grayzel | QTTB | Stock Option (Right to Buy) | Award | 16,363 | 16,363 | 15 Jan 2026 | Direct | |||
| Sven Ante Lundberg | QTTB | Stock Option (Right to Buy) | Award | 20,363 | 20,363 | 15 Jan 2026 | Direct | |||
| Kathleen Laporte | QTTB | Stock Option (Right to Buy) | Award | 23,272 | 23,272 | 15 Jan 2026 | Direct | |||
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -18.5% | $77,871 | $3.46 | -22,506 | 99,000 | 02 Dec 2025 | Direct |
| Lee Kalowski | QTTB | Common Stock | Sale | -18.5% | $31,395 | $3.46 | -9,072 | 39,938 | 02 Dec 2025 | Direct |
| Sven Ante Lundberg | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Iwicki Mark T. | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Isaac Manke | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Diyong Xu | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Mary Thistle | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| David S. Grayzel | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Arthur Tzianabos | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Kathleen Laporte | QTTB | Stock Option (Right to Buy) | Award | 53,521 | 53,521 | 23 Oct 2025 | Direct | |||
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -7.95% | $18,900 | $1.80 | -10,494 | 121,506 | 26 Aug 2025 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Sale | -4.87% | $5,385 | $1.80 | -2,990 | 58,384 | 26 Aug 2025 | Direct |
| Lee Kalowski | QTTB | Common Stock | Sale | -7.96% | $7,636 | $1.80 | -4,240 | 49,010 | 26 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.